Is BPC-157 legal in the US?

By The Docket DeskResearched & sourcedUpdated 17 Oct 2026

The short answer

No — BPC-157 is not an FDA-approved drug, and it is not currently legal to compound either. In April 2026 the FDA removed it from Category 2 (because the nominations were withdrawn), but did not move it to Category 1, leaving it in a regulatory gray zone. On July 23, 2026 the committee voted to recommend it — an advisory step, not authorization.

FDA approvalNot approved

Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized

PCAC recommendationRecommended for compounding (Jul 23, 2026) — advisory only; FDA rulemaking required

Use under reviewUlcerative colitis

Earliest pharmacy access2027 at the earliest (if cleared)

Approved vs compoundable vs “research-use” — the distinction that matters

An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 BPC-157 was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.

What happened on July 23

The FDA’s Pharmacy Compounding Advisory Committee heard the evidence and voted to recommend adding BPC-157 to the 503A list for ulcerative colitis. That vote is advisory only; the FDA must still issue a final rule before any pharmacy could legally compound it. Realistic patient access, if it happens at all, is 2027 at the earliest — as of September 2026 the FDA has not issued a proposed rule. BPC-157 and TB-500 went before the committee on the same day and drew the same 8–6 vote; BPC-157 vs TB-500 sets the two side by side.

Will BPC-157 become legal in 2026?+

Not automatically. The committee voted to recommend it on July 23, 2026, but that vote is advisory only — the FDA must still issue a final rule, which typically takes months. Realistic legal compounded access is 2027 at the earliest, and only if both steps go through; as of September 2026 no proposed rule has been issued.

Is “research-grade” BPC-157 the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.